The agreement allows Stason to use, develop, market, sell, offer for sale, distribute, import and export products based on the tissue necrosis therapy (TNT) technologies. The agreement also allows Stason to sell TNT products in the Asia-Pacific Economic Cooperation (APEC) territories with their strategic partners. This license enables Stason to use Lonza’s proprietary GS System™ and Stonsa’s TNT technologies to manufacture and commercialise innovative therapeutic and diagnostic products based on chimeric and fully human TNT monoclonal antibodies (mAbs). Stonsa Biopharm, Inc., a strategic partner of Stason, is the principal sub-licensee of the TNT and GS System™ technologies.

The TNT technology platform uses recombinant mAbs to target intracellular antigens in dead or dying (necrotic) tissues. These technologies have demonstrated a broad-spectrum therapeutic and diagnostic potential in solid tumors, including brain, lung, colon, breast, liver, prostate, and pancreatic cancers. Cotara^®, a chimeric TNT monoclonal antibody conjugated with a radioisotope Iodine-131 is currently being evaluated in phase 1 and 2 clinical trials in the US and India for the treatment of patients with glioblastoma multiforme, the deadliest form of brain cancer. Cotara^® had been also tested in conjunction with intravenous treatment of advanced colon cancer in a phase 1 clinical trial at Stanford University and radioablation therapy in a phase 1 trial at the Mayo Clinic.